A novel allogeneic chimeric antigen receptor (CAR) T-cell therapy, ALLO-501A, showed encouraging safety and efficacy in a small single-arm, open-label, phase 1/2 trial in heavily pretreated patients with advanced relapsed/refractory large B-cell lymphoma, with signs of increased efficacy for consolidation dosing.
Given its safety profile to date, consolidation dosing could be given even in the outpatient setting, according to the trial investigators, who presented the results at the 2021 annual